Evidence map›Paper›PMID 42395020›Full record

ArticleJournal of ginseng research2026

Ginseng-containing Shentao Ruangan (STR) formula alleviates hepatic fibrosis via hepatocellular Nrf2-ROS-TGF-β axis regulating hepatocyte-HSC crosstalk: Integrating single-cell RNA sequencing and multi-tiered validation.

Shangyi Huang, Ruisheng Zhou, Jing Li, Yi Zheng, Lunwei Yang, Tianqi Gao, Yi Yuan, Dailin Wu, Yafei Shi, Dayong Zheng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shangyi HuangState Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou University of Chinese Medicine, Guangzhou, China.
Ruisheng ZhouState Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jing LiState Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yi ZhengThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Lunwei YangThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Tianqi GaoThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Yi YuanThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Dailin WuThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Yafei ShiState Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou University of Chinese Medicine, Guangzhou, China.
Dayong ZhengDepartment of Oncology, Shunde Hospital, Southern Medical University, Foshan, 528399, China.
Daihan ZhouThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Ying TangState Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou University of Chinese Medicine, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The ginseng-containing Shentao Ruangan (STR) formula is clinically used for chronic liver conditions, including hepatic fibrosis. Guided by traditional Chinese medicine (TCM) principles, it targets the "deficiency leading to accumulation (Xu Sun Sheng Ji)" pathology in hepatic fibrosis via the "strengthening healthy qi and dispelling pathogenic factors (Fu Zheng Qu Xie)" mechanism. Aims: To elucidate how STR attenuates hepatic fibrosis, focusing on its regulation of the fibrotic liver microenvironment. Methods: Single-cell RNA sequencing profiled the fibrotic liver microenvironment; GEO analysis confirmed reactive oxygen species (ROS) as a central fibrotic driver. Results: Single-cell sequencing identified hepatocyte-hepatic stellate cell (HSC) crosstalk as a core fibrotic feature, with hepatocellular metabolic dysfunction and elevated ROS promoting fibrosis (GEO-validated). STR alleviated fibrosis and suppressed excessive hepatic ROS in vitro and Conclusion: This study links hepatocyte-HSC crosstalk/ROS-TGF-β-driven activation in hepatic fibrosis to TCM's "Xu Sun Sheng Ji", while STR's Nrf2-mediated antioxidant and anti-fibrotic actions embody "Fu Zheng Qu Xie", integrating TCM with modern medicine. STR, a ginseng-containing formula, is a promising targeted fibrosis therapy, advancing TCM-modern medicine integration.

Indexed as

Ginseng-containing Chinese medicine formulaHepatic fibrosisHepatocyte-HSC crosstalkNrf2-ROS-TGF-β axisSingle-cell RNA sequencingTCM

Identifiers

PMID42395020
PMCPMC13324126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.